Despite the difference in rat specie, dose and route of administration, the studies of Matveyenko et al. (2009), using a DPP IV inhibitor, and of Nachnani et al. (2010) [41], using an injection of GLP-1 agonist to enhance endogenous GLP-1 levels, raise the possibility that the enhancement of endogenous GLP-1 levels could induce undetected low grade asymptomatic chronic pancreatitis. The gene discussed is DPP4; the disease is chronic pancreatitis.